

**From:** PBAC (External)  
**To:** [REDACTED]  
**Subject:** RE: Advice required on submission pathway [SEC=UNCLASSIFIED]  
**Date:** Thursday, 9 August 2018 8:59:22 AM  
**Attachments:** [image001.png](#)

---

Dear [REDACTED]

Thanks for your email and I apologise for our delayed reply.

[REDACTED]

I hope this information is useful.

Regards,

[REDACTED]  
**PBAC Secretariat**

[PBAC@health.gov.au](mailto:PBAC@health.gov.au)

Department of Health

Health Technology Assessment Team | Assessment Branch | Technology Assessment and Access Branch

GPO Box 9848, CANBERRA ACT 2601 [REDACTED]

---

**From:** [REDACTED] @tevapharm.com]

**Sent:** Wednesday, 25 July 2018 6:27 PM

**To:** PBAC

**Subject:** Advice required on submission pathway [SEC=No Protective Marking]

Dear Secretariat

Teva Pharma Australia currently has a TGA registration application in review for a bioequivalent brand of Spiriva (tiotropium), under the tradename Braltus.

[REDACTED]



This message is intended solely for the designated recipient(s). It may contain confidential or proprietary information and may be subject to attorney-client privilege or other confidentiality protections. If you are not a designated recipient you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.

---

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."